Isomorphic Labs in funding talks at a $40B valuation: AI drug design gets a pharma-scale price tag
Alphabet-backed Isomorphic Labs is in early talks to raise new funding at a valuation of at least $40 billion, Bloomberg reports — potentially $50 billion — just five months after its $2.1 billion Series B. The proposed price tests whether investors believe AI-designed drugs can survive contact with the clinic.
- The talks are early and the financing has not closed; Bloomberg, citing people familiar with the effort, reports a valuation of at least $40 billion — one person said it could reach $50 billion, though terms could change. Investors and the amount sought were not identified.
- In May 2026 Isomorphic Labs raised a $2.1 billion Series B led by Thrive Capital, with Alphabet and GV alongside new backers MGX, Temasek, CapitalG, and the UK Sovereign AI Fund — following a $600 million external round in March 2025, also led by Thrive Capital.
- Isomorphic Labs was formed in 2021 as a spinout of Google DeepMind, with Demis Hassabis building it around AlphaFold's breakthrough in predicting protein structures; it has pushed beyond prediction toward a full drug-design engine, with collaborations announced with Eli Lilly and Novartis in 2024 — which the company said could be worth nearly $3 billion in upfront and milestone payments — plus expanded Novartis work and a research partnership with Johnson & Johnson.
- The counter-view: no AI-designed medicine has yet reached the market, and clinical trials remain the brutal filter every AI drug-discovery company must pass; a $50 billion figure would make Isomorphic worth more than most mid-cap pharmaceutical companies on the strength of models alone.
- Alphabet's other big bets show the playbook: Waymo raised $16 billion at a $126 billion valuation earlier this year.
The talks are early, and the financing has not closed. Bloomberg reports that Isomorphic Labs — the AI drug-discovery company founded by DeepMind CEO Demis Hassabis — is in discussions to raise new funding at a valuation of at least $40 billion, according to people familiar with the effort. One person told Bloomberg the figure could reach $50 billion, though the terms could still change. The report does not identify investors in the talks or say how much Isomorphic is seeking to raise.
Five months after $2.1 billion
The new talks land strikingly soon after the company's last round. In May 2026, Isomorphic Labs raised a $2.1 billion Series B led by Thrive Capital, with participation from Alphabet and GV alongside new backers MGX, Temasek, CapitalG, and the UK Sovereign AI Fund. That followed a $600 million external round in March 2025, also led by Thrive Capital, with GV and Alphabet participating.
The AlphaFold inheritance
Isomorphic Labs was formed in 2021 as a spinout of Google DeepMind, with Hassabis building it around AlphaFold's breakthrough in predicting protein structures. The company has since pushed beyond prediction toward a full drug-design engine: it announced collaborations with Eli Lilly and Novartis in 2024 — which the company said could be worth nearly $3 billion in upfront and milestone payments — and later expanded its Novartis work and added a research partnership with Johnson & Johnson.
What the valuation is really pricing
A $40 billion valuation is not a reward for results — it is a bet on a chain that hasn't been completed. No AI-designed medicine has yet reached the market, and clinical trials remain the brutal filter every AI drug-discovery company must pass. The company's own reported work — computationally designed molecules tested in the lab, preclinical programs — is company-reported, not independent proof. The counter-view making the rounds: the sector keeps raising larger checks before the first proof of clinical efficacy arrives, and a $50 billion figure would make Isomorphic worth more than most mid-cap pharmaceutical companies on the strength of models alone.
Still, the demand side is real and growing. OpenAI recently released a model aimed at life-sciences research, and Alphabet's other big bets show the playbook: Waymo raised $16 billion at a $126 billion valuation earlier this year. If the talks close anywhere near the reported numbers, Isomorphic Labs would become one of the most valuable AI companies ever to raise money on a promise of curing disease rather than selling software.
Sources: RuntimeWire (Oct. 8, 2026, citing Bloomberg Technology); Bloomberg Law (Oct. 8, 2026, carrying the Bloomberg report); The Hindu BusinessLine (May 2026, on the $2.1B Series B); AInvest (on the March 2025 $600M round).
Frequently asked questions
What is Isomorphic Labs raising and at what valuation?
Early talks to raise new funding at a valuation of at least $40 billion — potentially $50 billion, per Bloomberg's sources — just five months after its $2.1 billion Series B. The talks have not closed and the investors and amount sought were not identified.
What is Isomorphic Labs?
An AI drug-discovery company formed in 2021 as a Google DeepMind spinout, founded by DeepMind CEO Demis Hassabis around AlphaFold's protein-structure breakthrough. It has pushed beyond prediction toward a full drug-design engine: computationally designed molecules tested in the lab, preclinical programs, and partnerships with Eli Lilly, Novartis and Johnson & Johnson.
Is a $40B valuation justified?
A $40 billion valuation is not a reward for results — it's a bet on a chain that hasn't been completed: no AI-designed medicine has yet reached the market, and clinical trials remain the brutal filter. The counter-view making the rounds is that the sector keeps raising larger checks before the first proof of clinical efficacy arrives.